Assessment of Homologous Recombination Deficiency in Ovarian Cancer.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Accurately assessing homologous recombination deficiency to use as predictive biomarker is an area of intense research in ovarian cancer. Validated assays have demonstrated utility in determining maintenance therapy following platinum sensitive chemotherapy. Novel functional assays promise the potential to reflect HRD in real time and predict response to PARP inhibitors.

Keyphrases

dna repair
dna damage
high throughput
replacement therapy
oxidative stress
locally advanced
big data
machine learning
squamous cell carcinoma
mesenchymal stem cells
human health
bone marrow
stem cells
deep learning
risk assessment
radiation therapy
artificial intelligence
single cell
cell therapy